KMTS
Kestra Medical Technologies Ltd
$28.51
▲ 2.1%Updated Today 11:10 AM ET
KMTS at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
—
Interest Coverage
—
Current Ratio
4.41x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Kestra Medical Technologies Ltd (KMTS) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $95.13M in revenue and posted a net loss of $131.61M.
Our model rates KMTS Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
2Y CAGR
84.9%
Revenue moved from $27.81M in 2024 to $95.13M in 2026, a 84.9% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
51.4%
Operating Margin
-141.6%
Net Margin
-138.4%
ROE
—
Total Debt
$42.65M
Net Debt
-$57.06M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 4.4x. Detailed balance-sheet leverage is limited for this name. It carries roughly $42.65M of total debt against $99.71M of cash.
Operating CF
-$81.70M
Free Cash Flow
-$116.59M
FCF Margin
-122.6%
In the latest year Kestra Medical Technologies Ltd produced about -$81.70M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
KMTS trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where KMTS sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How KMTS stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), KMTS ranks #201 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#201
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $28.51 today · expected CAGR -50% – -45%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $102.74M | $110.95M | $119.83M | $129.42M | $139.77M |
| Net income | $3.08M | $3.33M | $3.59M | $3.88M | $4.19M |
| EPS | $0.05 | $0.06 | $0.06 | $0.07 | $0.07 |
| Share price (low) | $0.63 | $0.68 | $0.74 | $0.80 | $0.86 |
| Share price (high) | $1.05 | $1.14 | $1.23 | $1.33 | $1.43 |
| CAGR (low–high) | -98% / -96% | -85% / -80% | -70% / -65% | -59% / -54% | -50% / -45% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for KMTS:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against KMTS:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Kestra Medical Technologies Ltd is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 13 Wall Street analysts covering KMTS recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
KMTS's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
KMTS — frequently asked questions
Is KMTS a good stock to buy?
We don't give buy or sell advice. Review Kestra Medical Technologies Ltd's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does KMTS's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Kestra Medical Technologies Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for KMTS calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this KMTS analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell KMTS. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.